Join us for an installment of our Bionano In Motion webinar series as our speakers delve into immunotherapies and the emerging role of optical genome mapping (OGM) in assessing genome integrity as ...

A phase II study of hyper-CVAD with blinatumomab (blina) and inotuzumab ozogamicin (INO) for newly diagnosed Philadelphia chromosome (Ph)–negative B-cell acute lymphoblastic leukemia (ALL).

Cancer genomics, a young and evolving field, seeks to comprehensively examine all gene alterations and expression differences across the entire genetic landscape. With their increasing sophistication, ...

SAN DIEGO, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Bionano Genomics, Inc. (Nasdaq: BNGO) today announced highlights from Day 2 of Bionano Symposium 2026, which focused on New Frontiers in Oncology and ...

Bionano Genomics, Inc. announced a groundbreaking study published in Modern Pathology, which highlights the effectiveness of optical genome mapping (OGM) in detecting bone and soft tissue tumors. This ...